S. E. Christensen
Aarhus University
33 Papers
578 Citations
S. E. Christensen is an academic researcher from Aarhus University. The author has contributed to research in topics: Somatostatin & Insulin. The author has an hindex of 18, co-authored 33 publications.
Chat about Author
Papers
Low cerebrospinal fluid somatostatin in Parkinson disease: an irreversible abnormality.
TL;DR: In 39 parkinsonian patients, CSF somatostatin content was 88.0 ± 4.1 pg per milliliter, which was about 40% less than in controls, and seems to be irreversible, to be present at the onset of symptoms, and to imply an irreparable functional or structural alteration of somatOSTatin-secreting neurons.
125
Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
S. E. Christensen,Jørgen Weeke,Hans Ørskov,Niels Møller,Allan Flyvbjerg,A. G. Harris,E. Lund,Jens Otto Lunde Jørgensen +7 more
TL;DR: Diurnal serum GH patterns were determined in 10 acromegalic patients, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release and in contrast to somatostatin, SMS 201‐995 did not inhibit TSH release.
94
Low somatostatin content in cerebrospinal fluid in multiple sclerosis. An indicator of disease activity
Kurt V. Sørensen,S. E. Christensen,Erik Dupont,Aage Prange Hansen,Ejner Pedersen,Hans Ørskov +5 more
TL;DR: In 27 patients with multiple sclerosis (MS), and in 10 control subjects of comparable age, percent ideal body weight and sex ratio, the cerebrospinal fluid (CSF) content of somatostatin was measured by radioimmunoassay.
91
A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients
TL;DR: It is suggested that augmented peripheral blood flow is responsible for the condition of cardiac hyperkinesia in short-term acromegaly and involved in the development of hypertension, which is a frequent complication of long- term acromegalic disease.
81
The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study
TL;DR: It is suggested that reduction of serum growth hormone levels by octreotide in acromegalic patients is associated with a decrease of the left ventricular wall thickness, but the wall thickness is not reduced to levels of normal control subjects.
75